In this interview, Jessica Rodrigues, MS, answers questions about barriers to the access of pre-exposure prophylaxis (PrEP), funding, stigma, and choices of PrEP. She also spoke about these topics during...
In this podcast, Jessica Rodrigues, with AVAC: Global Advocacy for HIV Prevention, speaks about ways communities can overcome barriers to the access of pre-exposure prophylaxis (PrEP), including ambitious...
In this podcast, Jessica Rodrigues, with AVAC: Global Advocacy for HIV Prevention, provides a description of a Dual Prevention Pill and why it can be used as a case study for future multipurpose...
In this interview, Jessica Rodrigues, MS, answers questions about barriers to the access of pre-exposure prophylaxis (PrEP), funding, stigma, and choices of PrEP. She also spoke about these topics during...
In this podcast, Jessica Rodrigues, with AVAC: Global Advocacy for HIV Prevention, speaks about ways communities can overcome barriers to the access of pre-exposure prophylaxis (PrEP), including ambitious...
In this podcast, Jessica Rodrigues, with AVAC: Global Advocacy for HIV Prevention, provides a description of a Dual Prevention Pill and why it can be used as a case study for future multipurpose...
In this podcast, Raphael Landovitz, MD, discusses the findings from his recent trial, HPTN 083, which indicates that long-acting cabotegravir injected once every 8 weeks is superior to daily oral TDF/FTC in...
